focus -WSS

focus

author：hotspot 2025-09-30 00:47:47 - browse：21

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Senate panel to vote on hospitals, PBMs, prisoner care

WSS

Living organ donors deserve priority status for transplants

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

First Opinion Podcast: How to protect health care in times of war

Senate panel to vote on hospitals, PBMs, prisoner care

Meta's Zuckerberg and Chan on track to put $50 billion into science

A public health expert passes on football's full body collisions for youths

explore

focus

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Emergency medicine has repudiated 'excited delirium.' Now what?

After affirmative action ruling, medical educators look to 'holistic review'

Biden's order seeks to regulate AI risk without stifling innovation

Peter Hotez and the public health issue of online harassment

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Medical leaders decry Supreme Court decision on affirmative action

Eli Lilly’s Mounjaro succeeds in second weight

As demand for Covid shots wanes, Moderna seeks its next success

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

explore

WHO may add ‘noma' to its list of neglected tropical diseases

Paying for Covid pills will soon shift to insurers

A public health expert passes on football's full body collisions for youths

Eli Lilly’s Mounjaro succeeds in second weight

Biden administration plans revamp of organ transplant system

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Wikipedia

knowledge

explore

explore